Conexeu Sciences Inc.
NASDAQ: CNXUReno, US · Founded 2022 · Nevada corporation · 13 employees on LinkedIn · 1 known investors
Find your way into Conexeu Sciences Inc.
144 people in our graph share verified history with the Conexeu Sciences Inc. team — schools, employers, funds. One of them is your warm intro.
Hans Keirsteadunlockedknows JEFF SHARPE · together at University of British Columbia (overlapped)
×6knows the team · via University of British Columbia
×5knows the team · via British Columbia Institute of Technology
Conexeu is developing CXU™, a collagen-based extracellular matrix (ECM) platform for soft-tissue regeneration intended as an alternative to static fillers, combining structural support with tissue in-growth and integration. The platform is positioned as a single formula and device with potential use across a range of human and animal regenerative medicine applications.
Founders & leadership
Conexeu Sciences Inc. was founded in 2022 by Mauricio Gonzalez-Ulloa and David Bogart.
MG
Mauricio Gonzalez-UlloaFounder & CEO
DB
David BogartinChief Commercial Officer, Co-Founder & DirectorFounder of Conexeu Sciences, which is developing CXU™, a collagen-based extracellular matrix platform for soft-tissue regeneration across human and animal regenerative medicine applications.
SD
STEPHEN D INOUYEExecutive
BP
BRIAN PILCHERinChief Medical OfficerBrian Pilcher is an executive with over 25 years of experience in pharmaceutical and medical device development, with expertise in wound healing, dermatology, and plastic surgery. He has led medical affairs functions and overseen preclinical and clinical programs through regulatory approval and commercialization at organizations ranging from startups to established companies.
JS
JEFF SHARPEinChief Executive Officer, Director2025–2025Jeff Sharpe is an executive with three decades of experience in biotech and cross-sector business development, having led early-stage companies through growth and public markets, raised over $100 million in private and public financings, and negotiated M&A transactions.
MH
MILES HARRISONinNamed on SEC filing
CC
CLAUDIA CHAVEZ-MUNOZNamed on SEC filing
SP
SEBASTIAN PURCELLNamed on SEC filing
AC
AB
APRIL BURKENamed on SEC filing
AB
ANA BASTIANI-POSNERNamed on SEC filing
Board
MW
MICHAEL WRIGHTBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$7.6M disclosed across 16 rounds · 2025–2026
▶$252.1KraisedSep 2026 · 2 investors · BiotechnologyRule 506(b)
▶$252.1KraisedSep 2026 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- DAVID R BOGARTExecutive Officer, Director
- MILES HARRISONExecutive Officer, Director
- AARON FARBERGDirector
- STEPHEN D INOUYEExecutive Officer
- CLAUDIA CHAVEZ-MUNOZExecutive Officer
- JEFF SHARPEDirector
- Z PAUL LORENCDirector
- SEBASTIAN PURCELLDirector
- BRIAN PILCHERExecutive Officer
- ANDREW COSTADirector
- APRIL BURKEDirector
- ANA BASTIANI-POSNERDirector
- Offering amount
- $252.1K
- Amount sold
- $252.1K
- First sale
- Sep 2026
- Incorporated
- Corporation, Nevada, 2022
- Federal exemptions
- 06b
▶$88.5KraisedAug 2026 · 3 investors · BiotechnologyRule 506(b)
▶$88.5KraisedAug 2026 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- DAVID R BOGARTExecutive Officer, Director
- MILES HARRISONExecutive Officer, Director
- AARON FARBERGDirector
- STEPHEN D INOUYEExecutive Officer
- CLAUDIA CHAVEZ-MUNOZExecutive Officer
- JEFF SHARPEDirector
- Z PAUL LORENCDirector
- SEBASTIAN PURCELLDirector
- BRIAN PILCHERExecutive Officer
- ANDREW COSTADirector
- APRIL BURKEDirector
- ANA BASTIANI-POSNERDirector
- Offering amount
- $88.5K
- Amount sold
- $88.5K
- First sale
- Aug 2026
- Incorporated
- Corporation, Nevada, 2022
- Federal exemptions
- 06b
▶$62.7KraisedJul 2026 · 2 investors · BiotechnologyRule 506(b)
▶$62.7KraisedJul 2026 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- DAVID R BOGARTExecutive Officer, Director
- MILES HARRISONExecutive Officer, Director
- AARON FARBERGDirector
- STEPHEN D INOUYEExecutive Officer
- CLAUDIA CHAVEZ-MUNOZExecutive Officer
- JEFF SHARPEDirector
- Z PAUL LORENCDirector
- SEBASTIAN PURCELLDirector
- BRIAN PILCHERExecutive Officer
- ANDREW COSTADirector
- APRIL BURKEDirector
- ANA BASTIANI-POSNERDirector
- Offering amount
- $62.7K
- Amount sold
- $62.7K
- First sale
- Jul 2026
- Incorporated
- Corporation, Nevada, 2022
- Federal exemptions
- 06b
▶$203raisedJun 2026 · 1 investors · BiotechnologyRule 506(b)
▶$203raisedJun 2026 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- APRIL BURKEDirector
- AARON FARBERGDirector
- ANA BASTIANI-POSNERDirector
- MILES HARRISONExecutive Officer, Director
- SEBASTIAN PURCELLDirector
- JEFF SHARPEDirector
- Z PAUL LORENCDirector
- BRIAN PILCHERExecutive Officer
- DAVID R BOGARTExecutive Officer, Director
- STEPHEN D INOUYEExecutive Officer
- ANDREW COSTADirector
- CLAUDIA CHAVEZ-MUNOZExecutive Officer
- Offering amount
- $466K
- Amount sold
- $203
- First sale
- Jun 2026
- Incorporated
- Corporation, Nevada, 2022
- Federal exemptions
- 06b
▶$86.3KraisedJun 2026 · 2 investors · BiotechnologyRule 506(b)
▶$86.3KraisedJun 2026 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- DAVID R BOGARTExecutive Officer, Director
- MILES HARRISONExecutive Officer, Director
- CLAUDIA CHAVEZ-MUNOZExecutive Officer
- STEPHEN D INOUYEExecutive Officer
- ANA BASTIANI-POSNERDirector
- SEBASTIAN PURCELLDirector
- JEFF SHARPEDirector
- BRIAN PILCHERExecutive Officer
- ANDREW COSTADirector
- APRIL BURKEDirector
- Z PAUL LORENCDirector
- AARON FARBERGDirector
- Offering amount
- $86.3K
- Amount sold
- $86.3K
- First sale
- Jun 2026
- Incorporated
- Corporation, Nevada, 2022
- Federal exemptions
- 06b
▶$1.7KraisedJun 2026 · 3 investors · BiotechnologyRule 506(b)
▶$1.7KraisedJun 2026 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- CLAUDIA CHAVEZ-MUNOZExecutive Officer
- JEFF SHARPEDirector
- Z PAUL LORENCDirector
- STEPHEN D INOUYEExecutive Officer
- AARON FARBERGDirector
- MILES HARRISONExecutive Officer, Director
- BRIAN PILCHERExecutive Officer
- DAVID R BOGARTDirector
- SEBASTIAN PURCELLDirector
- Offering amount
- $2.2K
- Amount sold
- $1.7K
- First sale
- Jun 2025
- Incorporated
- Corporation, Nevada, 2022
- Federal exemptions
- 06b
▶$22.9KraisedJun 2026 · 1 investors · BiotechnologyRule 506(b)
▶$22.9KraisedJun 2026 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- SEBASTIAN PURCELLDirector
- MILES HARRISONExecutive Officer, Director
- STEPHEN D INOUYEExecutive Officer
- AARON FARBERGDirector
- Z PAUL LORENCDirector
- BRIAN PILCHERExecutive Officer
- JEFF SHARPEDirector
- DAVID R BOGARTDirector
- CLAUDIA CHAVEZ-MUNOZExecutive Officer
- Offering amount
- $137.4K
- Amount sold
- $22.9K
- First sale
- May 2026
- Incorporated
- Corporation, Nevada, 2022
- Federal exemptions
- 06b
▶$44.7KraisedMay 2026 · 1 investors · BiotechnologyRule 506(b)
▶$44.7KraisedMay 2026 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- DAVID R BOGARTDirector
- SEBASTIAN PURCELLDirector
- JEFF SHARPEDirector
- MILES HARRISONExecutive Officer, Director
- STEPHEN D INOUYEExecutive Officer
- AARON FARBERGDirector
- BRIAN PILCHERExecutive Officer
- CLAUDIA CHAVEZ-MUNOZExecutive Officer
- Z PAUL LORENCDirector
- Offering amount
- $44.7K
- Amount sold
- $44.7K
- First sale
- May 2026
- Incorporated
- Corporation, Nevada, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Conexeu Sciences Sets September and October 2026 Conference Schedule | The Manila Timesmanilatimes.net · Sep 2026
Conexeu to Present at 2026 Controversies & Conversations in Laser & Cosmetic Surgery Symposium on the Role of the Extracellular Matrix in Tissue Regeneration | The Manila Timesmanilatimes.net · Aug 2026Frequently asked questions
- What does Conexeu Sciences Inc. do?
- Conexeu is developing CXU™, a collagen-based extracellular matrix (ECM) platform for soft-tissue regeneration intended as an alternative to static fillers, combining structural support with tissue in-growth and integration. The platform is positioned as a single formula and device with potential use across a range of human and animal regenerative medicine applications.
- Who founded Conexeu Sciences Inc.?
- Conexeu Sciences Inc. was founded by Mauricio Gonzalez-Ulloa, David Bogart in 2022.
- Who are Conexeu Sciences Inc.'s investors?
- Conexeu Sciences Inc.'s investors include Innovation UBC.
- How much funding has Conexeu Sciences Inc. raised?
- Conexeu Sciences Inc. has disclosed $7.6M raised across 16 rounds.
- Where is Conexeu Sciences Inc. headquartered?
- Conexeu Sciences Inc. is headquartered in Reno, US.